| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8676285 | Revista Colombiana de Cardiología | 2017 | 9 Pages |
Abstract
Dual antiplatelet therapy (DAPT) with acetylsalicylic acid plus a platelet ADP P2Y12 receptor inhibitor is key in avoiding thrombosis following balloon angioplasty, or angioplasty with stent implantation. The main risk of DAPT is bleeding. The length of DAPT treatment depends on the comprehensive assessment of the patient's risk of thrombotic-ischemic complications and risk of bleeding. Depending on the clinical condition, treatment guidelines from the various societies recommend at least six months of dual treatment (and ideally one year), in patients with acute coronary syndrome.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Cardiology and Cardiovascular Medicine
Authors
Sergio H. Vásquez, Boris E. Vesga, Héctor J. Hernández,